ATAI - ATA Inc-China Stock Price, Fair Value and News

1.88USD-0.09 (-4.57%)Market Closed

Market Summary

USD1.88-0.09

Market Closed

-4.57%

ATAI Alerts

1 major insider sales recently.

ATAI Stock Price

View Fullscreen

ATAI RSI Chart

ATAI Valuation

Market Cap

312.1M

Price/Earnings (Trailing)

-3.32

Price/Sales (Trailing)

994.04

EV/EBITDA

-7.77

Price/Free Cashflow

-3.7

ATAI Price/Sales (Trailing)

ATAI Profitability

EBT Margin

-12511.62%

Return on Equity

-38.75%

Return on Assets

-32.08%

Free Cashflow Yield

-27.03%

ATAI Fundamentals

ATAI Revenue

Revenue (TTM)

314.0K

Rev. Growth (Yr)

-52.63%

Rev. Growth (Qtr)

-79.31%

ATAI Earnings

Earnings (TTM)

-94.2M

Earnings Growth (Yr)

-60.46%

Earnings Growth (Qtr)

-263.24%

Breaking Down ATAI Revenue

Last 7 days

-5.1%

Last 30 days

13.3%

Last 90 days

8.1%

Trailing 12 Months

1.1%

How does ATAI drawdown profile look like?

ATAI Financial Health

Current Ratio

9.22

Debt/Equity

0.06

Debt/Cashflow

-5.59

ATAI Investor Care

Shares Dilution (1Y)

0.08%

Diluted EPS (TTM)

-0.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	252.0K	271.0K	334.0K	314.0K
2022	0	13.7M	6.9M	233.0K
2021	0	0	0	20.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ATA Inc-China

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	johnson anne nagengast	sold	-50,708	1.85	-27,410	chief financial officer
Apr 02, 2024	kirpekar sahil	sold	-66,231	1.85	-35,801	chief business officer
Apr 02, 2024	rao srinivas	sold	-114,034	1.85	-61,640	see remarks
Mar 14, 2024	johnson anne nagengast	acquired	-	-	100,000	chief financial officer
Mar 14, 2024	kirpekar sahil	acquired	-	-	100,000	chief business officer
Mar 14, 2024	rao srinivas	acquired	-	-	175,000	see remarks
Mar 14, 2024	brand florian	acquired	-	-	350,000	see remarks
Nov 16, 2023	brand florian	bought	23,120	1.156	20,000	see remarks
Sep 13, 2023	brand florian	bought	57,968	1.4492	40,000	see remarks
Mar 29, 2023	brand florian	bought	103,558	1.4794	70,000	see remarks

Which funds bought or sold ATAI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Hunter Perkins Capital Management, LLC	unchanged	-	11,000	38,000	0.01%
Apr 23, 2024	Venturi Wealth Management, LLC	new	-	591	591	-%
Apr 23, 2024	Strategic Blueprint, LLC	unchanged	-	7,560	26,595	-%
Apr 23, 2024	Global Retirement Partners, LLC	added	1,250	1,979	2,128	-%
Apr 19, 2024	Westside Investment Management, Inc.	unchanged	-	1,262	4,717	-%
Apr 19, 2024	CALDWELL SUTTER CAPITAL, INC.	unchanged	-	280	985	-%
Apr 18, 2024	QUATTRO FINANCIAL ADVISORS LLC	new	-	139,823	139,823	0.04%
Apr 18, 2024	AlphaMark Advisors, LLC	unchanged	-	-	-	-%
Apr 17, 2024	CRA Financial Services, LLC	new	-	25,419	25,419	0.01%
Apr 15, 2024	JANICZEK WEALTH MANAGEMENT, LLC	unchanged	-	119	418	-%

Are Funds Buying or Selling ATAI?

Are funds buying ATAI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATAI

No. of Funds

ATAI Alerts

1 major insider sales recently.

Unveiling ATA Inc-China's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	apeiron investment group ltd.	20.1%	33,885,999	SC 13G/A
Feb 10, 2023	apeiron investment group ltd.	19.4%	32,671,702	SC 13G/A
Mar 01, 2022	galaxy group funding eci u llc	6.7%	10,796,736	SC 13G
Feb 10, 2022	apeiron investment group ltd.	19.7%	32,059,504	SC 13G

Recent SEC filings of ATA Inc-China

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	DEF 14A	DEF 14A
Apr 17, 2024	4	Insider Trading
Apr 12, 2024	PRE 14A	PRE 14A
Apr 08, 2024	144	Notice of Insider Sale Intent
Apr 05, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading

Peers (Alternatives to ATA Inc-China)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

ATA Inc-China News

Latest updates

ATA Inc-China Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-79.3%	18,000	87,000	172,000	37,000	38,000	24,000	127,000	230,000	266,000	-	19,880,000
Operating Expenses	24.7%	33,579,000	26,921,000	32,034,000	33,251,000	37,603,500	38,447,000	35,527,000	45,405,000	33,627,000	61,319,000	15,830,000
S&GA Expenses	42.5%	19,423,000	13,631,000	16,558,000	13,970,000	15,727,500	19,419,000	17,221,000	25,877,000	20,264,000	37,331,000	9,273,000
EBITDA Margin	32.9%	-115	-172	-499	-536	-577	-20.77	-10.08	-6.70	-	-	-
Interest Expenses	0.7%	690,500	686,000	658,000	622,000	923,000	-	-	-	-	-	-
Income Taxes	111.8%	423,500	200,000	185,000	200,000	6,033,000	100,000	51,000	3,557,000	400,000	58,000	6,000
Earnings Before Taxes	-141.8%	-18,319,500	43,847,000	-31,658,000	-33,156,000	-39,321,000	-33,134,000	-30,806,000	-48,579,000	-26,474,000	-67,301,000	5,753,000
EBT Margin	30.7%	-125	-180	-506	-541	-580	-20.79	-10.09	-6.70	-	-	-
Net Income	-263.2%	-72,223,500	44,244,000	-33,042,000	-33,135,000	-45,011,000	-33,887,000	-36,618,000	-88,877,000	-31,158,000	-48,461,000	688,000
Net Income Margin	-49.6%	-299	-200	-535	-589	-654	-28.25	-14.17	-8.24	-	-	-
Free Cashflow	-19.2%	-21,970,000	-18,431,000	-22,585,000	-21,391,000	-30,647,000	-28,504,000	-22,047,000	-20,561,000	-27,933,000	1,774,000	-16,699,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-4.8%	293	308	254	281	305	343	349	384	414	484	506	112
Current Assets	-14.0%	186	216	243	268	287	317	324	349	375	442	458	100
Cash Equivalents	-41.2%	45.00	76.00	141	186	191	143	84.00	124	362	430	454	97.00
Net PPE	-1.1%	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	23.8%	49.00	40.00	38.00	40.00	40.00	47.00	29.00	29.00	28.00	21.00	21.00	16.00
Current Liabilities	2.2%	20.00	20.00	18.00	20.00	20.00	26.00	22.00	22.00	21.00	15.00	14.00	12.00
Short Term Borrowings	-	109	-	-	-	-	-	-	-	-	0.00	0.00	-
Long Term Debt	0.6%	15.00	15.00	15.00	15.00	15.00	15.00	-	-	-	-	-	-
Shareholder's Equity	-8.8%	243	266	213	237	261	289	312	346	377	453	475	91.00
Retained Earnings	-3.4%	-550	-532	-576	-543	-510	-465	-431	-394	-357	-268	-237	-189
Additional Paid-In Capital	-0.6%	795	799	792	783	774	762	746	735	725	709	691	262
Shares Outstanding	0.0%	166	166	166	166	166	155	154	154	161	134	132	115
Minority Interest	-39.4%	1.00	2.00	3.00	4.00	5.00	7.00	8.00	8.00	9.00	10.00	10.00	5.00
Float	-	-	-	203	-	-	-	411	-	-	-	2,050	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-19.2%	-21.96	-18.43	-22.61	-21.11	-30.50	-28.04	-21.93	-23.99	-20.51	-28.11	2.00	-16.52	-	-	-
Share Based Compensation	-11.5%	7.00	8.00	9.00	9.00	12.00	11.00	10.00	10.00	13.00	12.00	38.00	0.00	-	-	-
Cashflow From Investing	98.2%	-0.82	-46.48	-22.00	16.00	80.00	66.00	-18.21	-214	-48.63	-0.61	-28.31	-3.72	-	-	-
Cashflow From Financing	-Infinity%	-8.46	-	-0.10	0.00	-0.92	20.00	2.00	0.00	2.00	4.00	374	30.00	-	-	-

ATAI Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
License revenue	$ 314	$ 233
Operating expenses:
Research and development	62,203	74,313
Acquisition of in-process research and development	0	357
General and administrative	63,582	70,350
Total operating expenses	125,785	145,020
Loss from operations	(125,471)	(144,787)
Other income, net:
Interest income	1,847	548
Interest expense	(2,656)	(923)
Benefit from research and development tax credit	2,445	0
Change in fair value of assets and liabilities, net	86,583	2,083
Impairment of other investments	(1,011)	0
Gain on deconsolidation of a variable interest entity, net	60	1,484
Foreign exchange gain (loss), net	(894)	6,902
Other expense, net	(189)	(489)
Total other income, net	86,185	9,605
Loss before income taxes	(39,286)	(135,182)
Provision for income taxes	(1,016)	(6,229)
Losses from investments in equity method investees, net of tax	(3,593)	(16,006)
Net loss	(43,895)	(157,417)
Net loss attributable to noncontrolling interests	(3,671)	(5,032)
Net loss attributable to ATAI Life Sciences N.V. stockholders	$ (40,224)	$ (152,385)
Basic Earnings Per Share	$ (0.25)	$ (0.98)
Diluted Earnings Per Share	$ (0.25)	$ (0.98)
Basic Weighted Average Number Of Shares Outstanding	158,833,785	155,719,585
Diluted Weighted Average Number Of Shares Outstanding	158,833,785	155,719,585

ATAI Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 45,034	$ 190,613
Securities carried at fair value	109,223	82,496
Committed Investment Funds	25,000	0
Prepaid expenses and other current assets	5,830	14,036
Short term notes receivable - related party, net	505	0
Total current assets	185,592	287,145
Property and equipment, net	981	928
Operating lease right-of-use asset, net	1,223	226
Other investments held at fair value	89,825	0
Other investments	1,838	6,755
Long term notes receivable - related parties, net	97	7,262
Convertible notes receivable - related party	11,202	0
Other assets	2,720	3,125
Total assets	293,478	305,441
Current liabilities:
Accounts payable	4,589	2,399
Accrued liabilities	15,256	17,306
Current portion of lease liability	275	180
Other current liabilities	0	12
Total current liabilities	20,120	19,897
Contingent consideration liability - related parties	620	953
Contingent consideration liability	1,637	0
Noncurrent portion of lease liability	990	44
Convertible promissory notes - related parties	164	415
Convertible promissory notes and derivative liability	2,666	0
Long-term debt, net	15,047	14,702
Other liabilities	7,918	3,664
Total liabilities	49,162	39,675
Commitments and contingencies (Note 16)
Stockholders' equity:
Common stock, 0.10 par value ($0.12 par value at December 31, 2023 and December 31, 2022); 750,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 166,026,396 and 165,935,914 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	18,573	18,562
Additional paid-in capital	794,787	774,092
Share subscription receivable	0	(24)
Accumulated other comprehensive loss	(19,460)	(21,702)
Accumulated deficit	(550,938)	(510,188)
Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders	242,962	260,740
Noncontrolling interests	1,354	5,026
Total stockholders' equity	244,316	265,766
Total liabilities and stockholders' equity	$ 293,478	$ 305,441

About ATA Inc-China

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

CEO	Mr. Florian Brand
WEBSITE	atai.life
INDUSTRY	Biotechnology
EMPLOYEES	133

ATA Inc-China Frequently Asked Questions

What is the ticker symbol for ATA Inc-China? What does ATAI stand for in stocks?

ATAI is the stock ticker symbol of ATA Inc-China. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ATA Inc-China (ATAI)?

As of Wed Apr 24 2024, market cap of ATA Inc-China is 312.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATAI stock?

You can check ATAI's fair value in chart for subscribers.

What is the fair value of ATAI stock?

You can check ATAI's fair value in chart for subscribers. The fair value of ATA Inc-China is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ATA Inc-China is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATAI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ATA Inc-China a good stock to buy?

The fair value guage provides a quick view whether ATAI is over valued or under valued. Whether ATA Inc-China is cheap or expensive depends on the assumptions which impact ATA Inc-China's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATAI.

What is ATA Inc-China's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, ATAI's PE ratio (Price to Earnings) is -3.32 and Price to Sales (PS) ratio is 994.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATAI PE ratio will change depending on the future growth rate expectations of investors.